Imatinib mesylate in the treatment of chronic myelogenous leukemia : Current therapeutic approach for chronic myeloid/Myeloproliferative disorder: Focus on imatinib mesylateBORTHAKUR, Gautam; CORTES, Jorge E.International journal of hematology. 2004, Vol 79, Num 5, pp 411-419, issn 0925-5710, 9 p.Article

Potential Cure of Acute Myeloid Leukemia : Analysis of 1069 Consecutive Patients in First Complete RemissionYANADA, Masamitsu; GARCIA-MANERO, Guillermo; BORTHAKUR, Gautam et al.Cancer. 2007, Vol 110, Num 12, pp 2756-2760, issn 0008-543X, 5 p.Article

Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemiaARIBI, Ahmed; BORTHAKUR, Gautam; RAVANDI, Farhad et al.Cancer. 2007, Vol 109, Num 4, pp 713-717, issn 0008-543X, 5 p.Article

Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous LeukemiaKONOPLEVA, Marina Y; WALTER, Roland B; HONGBO LU et al.Clinical cancer research (Print). 2014, Vol 20, Num 8, pp 2226-2235, issn 1078-0432, 10 p.Article

Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITDTAKAHASHI, Koichi; KANTARJIAN, Hagop; ESTROV, Zeev et al.British journal of haematology. 2013, Vol 161, Num 5, pp 659-666, issn 0007-1048, 8 p.Article

A Randomized Study of 2 Dose Levels of Intravenous Clofarabine in the Treatment of Patients With Higher-Risk Myelodysplastic SyndromeFADERL, Stefan; GARCIA-MANERO, Guillermo; KANTARJIAN, Hagop M et al.Cancer. 2012, Vol 118, Num 3, pp 722-728, issn 0008-543X, 7 p.Article

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experienceKANTARJIAN, Hagop; O'BRIEN, Susan; BORTHAKUR, Gautam et al.Blood. 2012, Vol 119, Num 9, pp 1981-1987, issn 0006-4971, 7 p.Article

Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia VeraQUINTAS-CARDAMA, Alfonso; KANTARJIAN, Hagop; VERSTOVSEK, Srdan et al.Journal of clinical oncology. 2009, Vol 27, Num 32, pp 5418-5424, issn 0732-183X, 7 p.Article

The Heterogeneous Prognosis of Patients With Myelodysplastic Syndrome and Chromosome 5 Abnormalities: How Does It Relate to the Original Lenalidomide Experience in MDS?KANTARJIAN, Hagop; O'BRIEN, Susan; GARCIA-MANERO, Guillermo et al.Cancer. 2009, Vol 115, Num 22, pp 5202-5209, issn 0008-543X, 8 p.Article

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndromeFADERL, Stefan; RAVANDI, Farhad; KANTARJIAN, Hagop M et al.Blood. 2008, Vol 112, Num 5, pp 1638-1645, issn 0006-4971, 8 p.Article

Challenges in Surgical Management of Abdominal Pain in the Neutropenic Cancer PatientBADGWELL, Brian D; CORMIER, Janice N; WRAY, Curtis J et al.Annals of surgery. 2008, Vol 248, Num 1, pp 104-109, issn 0003-4932, 6 p.Article

The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemiaGILES, Francis J; BORTHAKUR, Gautam; ALBITAR, Maher et al.British journal of haematology. 2007, Vol 136, Num 4, pp 624-627, issn 0007-1048, 4 p.Article

Treatment With FLT3 Inhibitor in Patients With FLT3-Mutated Acute Myeloid Leukemia Is Associated With Development of Secondary FLT3-Tyrosine Kinase Domain MutationsALVARADO, Yesid; KANTARJIAN, Hagop M; LUTHRA, Rajyalakshmi et al.Cancer. 2014, Vol 120, Num 14, pp 2142-2149, issn 0008-543X, 8 p.Article

Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication StatusCORTES, Jorge E; KANTARJIAN, Hagop; LEVIS, Mark et al.Journal of clinical oncology. 2013, Vol 31, Num 29, pp 3681-3687, issn 0732-183X, 7 p.Article

A Phase 1 Dose-Escalation Study of ARRY-520, a Kinesin Spindle Protein Inhibitor, in Patients With Advanced Myeloid LeukemiasJEAN KHOURY, Hanna; GARCIA-MANERO, Guillermo; KARAN, Sharon et al.Cancer. 2012, Vol 118, Num 14, pp 3556-3564, issn 0008-543X, 9 p.Article

Evaluating the Serial Use of the Myelofibrosis Symptom Assessment Form for Measuring Symptomatic Improvement: Performance in 87 Myelofibrosis Patients on a JAK1 and JAK2 Inhibitor (INCB018424) Clinical TrialMESA, Ruben A; KANTARJIAN, Hagop; PARDANANI, Animesh D et al.Cancer. 2011, Vol 117, Num 21, pp 4869-4877, issn 0008-543X, 9 p.Article

Daily Palonosetron Is Superior to Ondansetron in the Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting in Patients With Acute Myelogenous LeukemiaMATTIUZZI, Gloria N; CORTES, Jorge E; BLAMBLE, Deborah A et al.Cancer. 2010, Vol 116, Num 24, pp 5659-5666, issn 0008-543X, 8 p.Article

Dasatinib Early Intervention After Cytogenetic or Hematologic Resistance to Imatinib in Patients With Chronic Myeloid LeukemiaQUINTAS-CARDAMA, Alfonso; CORTES, Jorge E; O'BRIEN, Susan et al.Cancer. 2009, Vol 115, Num 13, pp 2912-2921, issn 0008-543X, 10 p.Article

Phase I/II Trial of AEG35156 X-Linked Inhibitor of Apoptosis Protein Antisense Oligonucleotide Combined With Idarubicin and Cytarabine in Patients With Relapsed or Primary Refractory Acute Myeloid LeukemiaSCHIMMER, Aaron D; ESTEY, Elihu H; BRANDWEIN, Joseph et al.Journal of clinical oncology. 2009, Vol 27, Num 28, pp 4741-4746, issn 0732-183X, 6 p.Article

Survival Is Poorer in Patients With Secondary Core-binding Factor Acute Myelogenous Leukemia Compared With De Novo Core-binding Factor LeukemiaBORTHAKUR, Gautam; LIN, E; JAIN, Nitin et al.Cancer. 2009, Vol 115, Num 14, pp 3217-3221, issn 0008-543X, 5 p.Article

Phase 1 Study of XL119, a Rebeccamycin Analog, in Patients With Refractory Hematologic MalignanciesBORTHAKUR, Gautam; ALVARADO, Yesid; RAVANDI-KASHANI, Farhad et al.Cancer. 2008, Vol 113, Num 2, pp 360-366, issn 0008-543X, 7 p.Article

Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapyBORTHAKUR, Gautam; KANTARJIAN, Hagop; DALEY, George et al.Cancer. 2006, Vol 106, Num 2, pp 346-352, issn 0008-543X, 7 p.Article

Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemiaNAZHA, Aziz; CORTES, Jorge; FADERL, Stefan et al.Haematologica (Roma). 2012, Vol 97, Num 8, pp 1242-1245, issn 0390-6078, 4 p.Article

Stem Cell Transplantation for Patients With Chronic Myeloid Leukemia Resistant to Tyrosine Kinase Inhibitors With BCR-ABL Kinase Domain Mutation T315IVELEV, Nikolai; CORTES, Jorge; CHAMPLIN, Richard et al.Cancer. 2010, Vol 116, Num 15, pp 3631-3637, issn 0008-543X, 7 p.Article

Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemiaTARN, Constantine S; KANTARJIAN, Hagop; GARCIA-MANERO, Guillermo et al.Blood. 2008, Vol 112, Num 3, pp 516-518, issn 0006-4971, 3 p.Article